Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

156455

registered interest
date	18/11/2014
answering body	Foreign and Commonwealth Office
answering dept id	16
answering dept short name	Foreign and Commonwealth Office
answering dept sort name	Foreign and Commonwealth Office
hansard heading	Sudan
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the ability of the United Nations Mission in Darfur to conduct a thorough investigation of reported mass rapes in Tabit during their visit on 4 November, in the light of the interruption of that visit by military intelligence personnel.
tabling member printed	Lord Avebury
uin	HL2897
answer	answer is ministerial correction date of answer 27/11/2014 answer text The refusal to allow the UN African Union Mission in Darfur (UNAMID) access to Tabit on 4 November prevented them from conducting a thorough investigation in to the very serious allegations of mass rapes. Some access was subsequently possible on 9 November but we continue to call on the Government of Sudan to allow UNAMID full and unhindered access to Tabit. answering member printed Baroness Anelay of St Johns question first answered 27/11/2014 14:54:53 answering member 3474 label Biography information for Baroness Anelay of St Johns
tabling member	1665 label Biography information for Lord Avebury

156456

registered interest
date	18/11/2014
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Falkland Islands
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they will revisit the circumstances in which the late Corporal McLaughlin was recommended for a gallantry award during the Falklands conflict which was subsequently withdrawn; and if not, why not.
tabling member printed	Lord Ashcroft
uin	HL2898
answer	answer is ministerial correction date of answer 01/12/2014 answer text <p>The noble lord will be aware of the hon. Member for Wallasey’s (Ms Eagle) Westminster Hall debate on 18 November about posthumous recognition for Corporal McLaughlin. Following the debate, the Minister of State for Defence, Personnel, Welfare and Veterans (Anna Soubry) and I have agreed that while a formal investigation is not an option, I will re-examine the facts surrounding recognition in this case. However, to be clear, no citation for an award was received for consideration by the Ministry of Defence and therefore it would be incorrect to say that Cpl McLaughlin had a recommendation withdrawn. The issue is that no citation was actually submitted for consideration by the Operational Awards Committee; a fact that is acknowledged by all parties.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member printed Lord Astor of Hever question first answered 01/12/2014 16:19:25 answering member 3428 label Biography information for Lord Astor of Hever attachment 1 file name Debate Corporal Stewart Mclaughlin 18 November 2014.doc title DebateHansard Extract 18 November 2014
tabling member	2568 label Biography information for Lord Ashcroft

156457

registered interest
date	18/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment the Medicines and Healthcare Products Regulatory Agency and the Advisory Committee for Malaria Prevention have made of the United States Food and Drug Administration's Safety Communication of 29 July 2013 warning of the risk of psychiatric and nerve side effects from taking Lariam (mefloquine) as a malaria prophylactic.
tabling member printed	Baroness Corston
uin	HL2899
answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>Mefloquine (brand name Lariam) is one of several drugs licensed for the prevention (<strong>c</strong>hemoprophylaxis) or treatment of malaria. As with any medicine, mefloquine may cause side effects in some people and the potential risks should be balanced against the expected benefits of therapy. Information on possible side effects is available to the medical profession via the Summary of Product Characteristics (SmPC), and to patients via the Patient Information Leaflet.</p><p> </p><p> </p><p> </p><p>In 2013, the Medicines and Healthcare products Regulatory Agency (MHRA) strengthened the warnings in the mefloquine SmPC, particularly regarding the well-established risk of neuropsychiatric side effects. The licence holder (Roche) also issued a letter to healthcare professionals at the end of October 2013 to increase awareness of these possible risks, alongside a prescriber checklist and patient alert card to aid compliance with the warnings. In November 2013, the MHRA issued a further communication to healthcare professionals on the risks of mefloquine via its Drug Safety Update bulletin:</p><p> </p><p> </p><p> </p><p>www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336723</p><p> </p><p> </p><p> </p><p>As with all medicines, the MHRA will keep the safety of mefloquine under continual review.</p><p> </p><p> </p><p> </p><p>The Advisory Committee for Malaria Prevention (ACMP) carefully considered all available data following the Food and Drug Administration’s safety communication and subsequent modification of the SmPC by Roche in September 2013. SmPC recommendations for monitoring of liver function and eye assessment in long term use have also been added to the guidelines. The ACMP continues to believe that mefloquine is a valuable option for prophylaxis against malaria when appropriate risk assessments are undertaken.</p><p> </p> answering member printed Earl Howe question first answered 02/12/2014 12:38:24 answering member 2000 label Biography information for Earl Howe
tabling member	215 label Biography information for Baroness Corston

156458

registered interest
date	18/11/2014
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Armed Forces: Mefloquine
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many serving (1) members of the armed forces, and (2) reservists, deployed to Sierra Leone in the ebola epidemic have been given Lariam (mefloquine) as a malaria prophylaxis.
tabling member printed	Baroness Corston
uin	HL2900
answer	answer is ministerial correction date of answer 01/12/2014 answer text <p>58 UK Armed Forces personnel who have been deployed on Operation GRITROCK before 31 October 2014 have been prescribed Mefloquine (commercially known as Lariam) as a malaria prophylaxis. All of these 58 were Regulars.</p><p> </p><p>The exact choice of antimalarial drug used by the military depends on a number of factors, including the region the individual is deploying to, their health and any past history of side effects. Malarone is the first choice drug for those Service personnel deploying on Operation GRITROCK. For those individuals unable to tolerate Malarone the second choice is Mefloquine. Doxycycline will be offered to those individuals who cannot tolerate Malorone or Mefloquine.</p><p> </p><p> </p> answering member printed Lord Astor of Hever question first answered 01/12/2014 16:13:10 answering member 3428 label Biography information for Lord Astor of Hever
tabling member	215 label Biography information for Baroness Corston